• Mashup Score: 1
    BIR Publications - 7 month(s) ago

    Artificial intelligence has been introduced to clinical practice, especially radiology and radiation oncology, from image segmentation, diagnosis, treatment planning and prognosis. It is not only crucial to have an accurate artificial intelligence model, but also to understand the internal logic and gain the trust of the experts. This review is intended to provide some insights into core concepts of the interpretability, the state-of-the-art methods for understanding the machine learning models, the evaluation of these methods, identifying some challenges and limits of them, and gives some examples of medical applications.

    Tweet Tweets with this article
    • RT @BJR_Radiology: Interpretable artificial intelligence in radiology and radiation oncology https://t.co/zoNFPG7MoA #RadOnc #Radiotherapy…

  • Mashup Score: 7

    People with low to medium-risk, localised prostate cancer can be treated as effectively using fewer and higher doses of radiation therapy delivered over five treatment sessions as they can with lower doses delivered over several weeks, according to researchers from The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London.

    Tweet Tweets with this article
    • "It's fantastic that advances in #Radiotherapy mean we can give patients treatment in a fraction of the standard time. This is a game-changer for patients." - Professor Emma Hall (@EmmaHall71), Co-Director of @ICR_CTSU, speaking about the PACE-B trial⬇️ https://t.co/kRRiI4htSr https://t.co/q28fMQs3Ns

  • Mashup Score: 1

    People with low to medium-risk, localised prostate cancer can be treated as effectively using fewer and higher doses of radiation therapy delivered over five treatment sessions as they can with lower doses delivered over several weeks, according to researchers from The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London.

    Tweet Tweets with this article
    • 🎯 NEWS: Advances in #Radiotherapy mean it’s now possible to treat low to medium-risk, localised #ProstateCancer in just five sessions. Results from the PACE-B trial led by @royalmarsdenNHS and the ICR will be presented at #ASTRO22 on Monday. Read more 👇 https://t.co/kRRiI4i1HZ